Curaleaf Holdings Past Earnings Performance
Past criteria checks 0/6
Curaleaf Holdings's earnings have been declining at an average annual rate of -42.8%, while the Pharmaceuticals industry saw earnings growing at 31.5% annually. Revenues have been growing at an average rate of 39.2% per year.
Key information
-42.8%
Earnings growth rate
-32.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 39.2% |
| Return on equity | -20.4% |
| Net Margin | -17.1% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Subdued Growth No Barrier To Curaleaf Holdings, Inc. (TSE:CURA) With Shares Advancing 25%
Jan 19
Does Curaleaf Holdings (CSE:CURA) Have A Healthy Balance Sheet?
Dec 11Is Curaleaf Holdings (CSE:CURA) Using Too Much Debt?
Sep 08Curaleaf Holdings (CSE:CURA) Has Debt But No Earnings; Should You Worry?
May 28We Think Curaleaf Holdings (CSE:CURA) Is Taking Some Risk With Its Debt
Sep 05Here's Why Curaleaf Holdings (CSE:CURA) Has A Meaningful Debt Burden
May 20Is Curaleaf Holdings (CSE:CURA) A Risky Investment?
Oct 26Loss-Making Curaleaf Holdings, Inc. (CSE:CURA) Set To Breakeven
Mar 20Is Curaleaf Holdings' (CSE:CURA) Share Price Gain Of 188% Well Earned?
Feb 27Calculating The Fair Value Of Curaleaf Holdings, Inc. (CSE:CURA)
Feb 01Curaleaf Holdings (CSE:CURA) Has A Somewhat Strained Balance Sheet
Jan 11
What Kind Of Investors Own Most Of Curaleaf Holdings, Inc. (CSE:CURA)?
Dec 24Revenue & Expenses BreakdownBeta
How Curaleaf Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,347 | -230 | 435 | 0 |
| 30 Sep 23 | 1,402 | -457 | 479 | 0 |
| 30 Jun 23 | 1,395 | -426 | 482 | 0 |
| 31 Mar 23 | 1,377 | -382 | 481 | 0 |
| 31 Dec 22 | 1,275 | -258 | 448 | 0 |
| 30 Sep 22 | 1,244 | -157 | 440 | 0 |
| 30 Jun 22 | 1,234 | -202 | 453 | 0 |
| 31 Mar 22 | 1,232 | -223 | 449 | 0 |
| 31 Dec 21 | 1,196 | -206 | 426 | 0 |
| 30 Sep 21 | 1,118 | -164 | 398 | 0 |
| 30 Jun 21 | 984 | -90 | 356 | 0 |
| 31 Mar 21 | 790 | -57 | 293 | 0 |
| 31 Dec 20 | 627 | -57 | 258 | 0 |
| 30 Sep 20 | 472 | -52 | 207 | 0 |
| 30 Jun 20 | 351 | -50 | 160 | 0 |
| 31 Mar 20 | 282 | -72 | 142 | 0 |
| 31 Dec 19 | 221 | -67 | 115 | 0 |
| 30 Sep 19 | 178 | -57 | 104 | 0 |
| 30 Jun 19 | 137 | -84 | 91 | 0 |
| 31 Mar 19 | 103 | -64 | 75 | 0 |
| 31 Dec 18 | 77 | -56 | 60 | 0 |
| 30 Sep 18 | 51 | -40 | 42 | 0 |
| 30 Jun 18 | 36 | -6 | 30 | 0 |
| 31 Mar 18 | 25 | -3 | 22 | 0 |
| 31 Dec 17 | 19 | -3 | 18 | 0 |
| 31 Dec 16 | 4 | 0 | 5 | 0 |
Quality Earnings: CURA is currently unprofitable.
Growing Profit Margin: CURA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CURA is unprofitable, and losses have increased over the past 5 years at a rate of 42.8% per year.
Accelerating Growth: Unable to compare CURA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CURA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: CURA has a negative Return on Equity (-20.4%), as it is currently unprofitable.